Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A methodologically sound single-centre internal validation study of prognostic nomograms with good discrimination (C-index 0.74–0.76) in a contemporary HER2-positive metastatic cohort, but limited by lack of specific treatment annotation and short median follow-up relative to the 5-year outcome estimates.
Early-stage preclinical and animal study demonstrating analgesic efficacy of thymoquinone in paclitaxel-induced neuropathy, but with limited structural neuroprotection and no human data, requiring confirmation before clinical translation.
Single-centre retrospective study of 141 patients with observational outcomes; no randomised comparator, no prospective design, and no hard clinical endpoints with effect sizes reported.
Systematic review and meta-analysis of 197 studies with 72,794 patients providing a pooled prevalence estimate with confidence interval; rigorous methodology but epidemiological rather than intervention-based evidence.
Real-world retrospective cohort study demonstrating clinically meaningful efficacy and safety of T-DXd in heavily pretreated HER2-positive metastatic breast cancer, but limited by single-center design, lack of comparator arm, and acknowledged biases in maintenance analysis.
High-quality meta-analysis of 23 Phase II/III RCTs (n=8797) demonstrating clinically meaningful improvements in DFS, OS, and pCR with carboplatin-containing chemotherapy in TNBC, with rigorous pooling and quantified safety trade-offs.
A single-centre retrospective study with prospective cardiac monitoring showing a high incidence of asymptomatic cardiotoxicity using contemporary biomarkers and strain imaging, but limited by retrospective design and lack of a control comparator.